Our Background
Isolation of human gut bacteria with specific properties (i.e. immune stimulatory and specific binding properties)
Isolation of strains expressing specific carbohydrate antigens
In vitro and In vivo evaluation of probiotic properties
Safety assessment including toxicological studies
Risk assessment and risk group downgrading of bacteria species, e.g. Bacteroides xylanisolvens
Obtaining Novel Food Status (EU) and GRAS Status (US) for a new Microorganism (DSM 23964)
Running probiotic specific Human Clinical Studies
Development of production processes from the lab to industrial scale